Lrp6 hypomorphic mutation affects bone mass through bone resorption in mice and impairs interaction with Mesd

Journal of Bone and Mineral Research

Volumn 23, Issue 10, 2008, Pages 1661-1671

  Kubota, Takuo ^a,b   Michigami, Toshimi ^b   Sakaguchi, Naoko ^b   Kokubu, Chikara ^c   Suzuki, Akira ^b   Namba, Noriyuki ^a   Sakai, Norio ^a   Nakajima, Shigeo ^a   Imai, Kenji ^d   Ozono, Keiichi ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b RESEARCH INSTITUTE FOR MATERNAL AND CHILD HEALTH   (Japan)

^c OSAKA UNIVERSITY   (Japan)

^d INSTITUTE OF EPIDEMIOLOGY   (Germany)

Author keywords

Bone resorption; Lrp6; Mesd; Rankl; Wnt signaling

Indexed keywords

CHAPERONE; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN 6; MUTANT PROTEIN; OSTEOCALCIN; OSTEOCLAST DIFFERENTIATION FACTOR; WNT PROTEIN;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BLOOD LEVEL; BONE EROSION; BONE MASS; BONE MINERALIZATION; CALVARIA; CELL COUNT; CELL MEMBRANE; CHEMICAL ANALYSIS; FEMALE; IN VITRO STUDY; IN VIVO STUDY; MESODERM; MORPHOMETRICS; NONHUMAN; OSTEOBLAST; OSTEOLYSIS; PHENOTYPE; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAT; SIGNAL TRANSDUCTION; TIBIA; TRABECULAR BONE; URINALYSIS; WILD TYPE;

ANIMALS; BONE DENSITY; BONE RESORPTION; CELL LINE; IMMUNOHISTOCHEMISTRY; LDL-RECEPTOR RELATED PROTEINS; MICE; MICE, INBRED BALB C; MOLECULAR CHAPERONES; MUTATION; TOMOGRAPHY, X-RAY COMPUTED;

EID: 52949105706     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1359/jbmr.080512     Document Type: Article

References (37)

1. NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy 2001 Osteoporosis prevention, diagnosis, and therapy. JAMA 285:785-795.
2. Peacock M, Turner CH, Econs MJ, Foround T 2002 Genetics of osteoporosis. Endocr Rev 23:303-326.
3. Ralston SH, de Crombrugghe B 2006 Genetic regulation of bone mass and susceptibility to osteoporosis. Genes Dev 20:2492-2506.
4. Boyden LM, Mao J, Belsky J, Mitzner L, Farhi A, Mitnick MA, Wu D, Insogna K, Lifton RP 2002 High bone density due to a mutation in LDL-receptor-related protein 5. N Engl J Med 346:1513-1521.
5. Gong Y, Slee RB, Fukai N, Rawadi G, Roman-Roman S, Reginato AM, Wang H, Cundy T, Lorieux FH, Lev D, Zacharin M, Oexle K, Marcelino J, Suwairi W, Heeger S, Sabatakos G, Apte S, Adkins WN, Allgrove J, Arslan-Kirchner M, Batch JA, Beighton P, Black GCM, Boles RG, Boon LM, Borrone C, Brunner HG, Carle GF, Dallapiccola B, De Paepe A, Floege B, Halfhide ML, Hall B, Hennekam RC, Hirose T, Jans A, Juppner H, Kim CA, Keppler-Noreuil K, Kohlschuetter A, LaCombe D, Lambert M, Lemyre E, Letteboer T, Peltonen L, Ramesar RS, Romanengo M, Somer H, Steichen-Gersdorf E, Steinmann B, Sullivan B, Superti-Furga A, Swoboda W, van den Boogaard MJ, Van Hul W, Vikkula M, Votruba M, Zabel B, Garcia T, Baron R, Olsen BR, Warman ML 2001 LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. Cell 107:513-523.
6. Little RD, Carulli JR, Del Mastro RG, Dupuis J, Osborne M, Folz C, Manning SP, Swain SM, Zhao SC, Eustace B, Lappe MM, Spitzer L, Zweier S, Braunschweiger K, Benchekroun Y, Hu X, Adair R, Chee L, FitzGerald MG, Tulig C, Caruso A, Tzellas N, Bawa A, Franklin B, McGuire S, Nogues X, Gong G, Allen KM, Anisowicz A, Morales AJ, Lomedico PT, Recker SM, Van Eerdewegh P, Recker RR, Johnson ML 2002 A mutation in the LDL receptor-related protein 5 gene results in the autosomal dominant high-bone-mass trait. Am J Hum Genet 70:11-19.
7. Kato M, Patel MS, Levasseur R, Lobov I, Chang BHJ, Glass DA II, Hartmann C, Li L, Hwang TH, Brayton CF, Lang RA, Karsenty G, Chan L 2002 Cbfa1-independent decrease in osteoblast proliferation, osteopenia, and persistent embryonic eye vascularization in mice deficient in Lrp5, a Wnt coreceptor. J Cell Biol 157:303-314.
8. Babij P, Zhao W, Small C, Kharode Y, Yaworsky PJ, Bouxsein ML, Reddy PS, Bodine PW, Robinson JA, Bhat B, Marzolf J, Moran RA, Bex F 2003 High bone mass in mice expressing a mutant LRP5 gene. J Bone Miner Res 18:960-974.
9. Baron R, Rawadi G 2007 Targeting the Wnt/β-catenin pathway to regulate bone formation in the adult skeleton. Endocrinology 148:2635-2643.
10. Glass DA II, Karsenty G 2007 In vivo analysis of Wnt signaling in bone. Endocrinology 148:2630-2634.
11. Krishnan V, Bryant HU, MacDougald BA 2006 Regulation of bone mass by Wnt signalling. J Clin Invest 116:1202-1209.
12. He X, Semenov M, Tamai K, Zheg X 2004 LDL receptor-related proteins 5 and 6 in Wnt/β-catenin signaling: Arrows point the way. Development 131:1663-1677.
13. Kelly OG, Pinson KI, Skarnes WC 2004 The Wnt co-receptors Lrp5 and Lrp6 are essential for gastrulation in mice. Development 131:2803-2815.
14. Pinson KI, Brennan J, Monkley S, Avery BJ, Skarnes WC 2000 An LDL-receptor-related protein mediates Wnt signalling in mice. Nature 407:535-538.
15. Logan CY, Nusse R 2004 The Wnt signaling pathway in development and disease. Annu Rev Cell Dev Biol 20:781-810.
16. Moon RT, Kohn AD, De Ferrari GD, Kaykas A 2004 Wnt and β-catenin signalling: Diseases and therapies. Nat Rev Genet 5:689-699.
17. Hsieh JC, Lee L, Zhang L, Wefer S, Brown K, DeRossi C, Wines ME, Rosenquist T, Holdener BC 2003 Mesd encodes an LRP5/6 chaperone essential for specification of mouse embryonic polarity. Cell 112:355-367.
18. Holmen SL, Giambernardi TA, Zylstra CR, Buckner-Berghuis BD, Resau JH, Hess JF, Glant V, Bouxsein ML, Ai M, Warman ML, Williams BO 2004 Decreased BMD and limb deformities in mice carrying mutations in both Lrp5 and Lrp6. J Bone Miner Res 19:2033-2040.
19. Mani A, Radhakrishnan J, Wang H, Mani A, Mani M-A, Nelson-Williams C, Carew KS, Mane S, Najmabadi H, Wu D, Lifton RP 2007 LRP6 mutation in a family with early coronary disease and metabolic risk factors. Science 315:1278-1282.
20. Kokubu C, Heinzmann U, Kokubu T, Sakai N, Kubota T, Kawai M, Wahl MB, Galceran J, Grosschedl R, Ozono K, Imai K 2004 Skeletal defects in ringelschwanz mutant mice reveal that Lrp6 is required for proper somitogenesis and osteogenesis. Development 131:5469-5480.
21. Parfitt AM, Drezner MK, Glorieux FH, Kanis JA, Malluche H, Meunier PJ, Ott SM, Recker RR 1987 Bone histomorphometry: Standardization of nomenclature, symbols, and units. J Bone Miner Res 2:595-610.
22. Bakker A, Klein-Nulend J 2003 Osteoblasts isolation from murine calvariae and long bones. In: Helfrich MH, Ralston SH (eds.) Bone Research Protocols. Humana Press, Totowa, NJ, USA, pp. 19-28.
23. Takahashi N, Yamana H, Yoshiki S, Roodman GD, Mundy GR, Jones SJ, Boyde A, Suda T 1988 Osteoclast-like cell formation and its regulation by osteotropic hormones in mouse bone marrow cultures. Endocrinology 122:1373-1382.
24. Carninci P, Kasukawa T, Katayama S, Gough J, Frith MC, Maeda N, Oyama R, Ravasi T, Lenhard B, Wells C, Kodzius R, Shimokawa K, Bajic VB, Brenner SE, Batalov S, Forrest AR, Zavolan M, Davis MJ, Wilming LG, Aidinis V, Allen JE, Ambesi-Impiombato A, Apweiler R, Aturaliya RN, Bailey TL, Bansal M, Baxter L, Beisel KW, Bersano T, Bono H, Chalk AM, Chiu CP, Choudhary V, Christoffels A, Clutterbuck DR, Crowe ML, Dalla E, Dalrymple BP, de Bono B, Della G, di Bernardo D, Down T, Engstrom P, Fagiolini M, Faulkner G, Fletcher CF, Fukushima T, Furuno M, Futaki S, Gariboldi M, Georgii-Hemming P, Gingeras TR, Gojobori T, Green RE, Gustincich S, Harbers M, Hayashi Y, Hensch TK, Hirokawa N, Hill D, Huminiecki L, Iacono M, Ikeo K, Iwama A, Ishikawa T, Jakt M, Kanapin A, Katoh M, Kawasawa Y, Kelso J, Kitamura H, Kitano H, Kollias G, Krishnan SP, Kruger A, Kummerfeld SK, Kurochkin IV, Lareau LF, Lazarevic D, Lipovich L, Liu J, Liuni S, McWilliam S, Madan B, Madera M, Marchionni L, Matsuda H, Matsuzawa S, Miki H, Mignone F, Miyake S, Morris K, Mottagui-Tabar S, Mulder N, Nakano N, Nakauchi H, Ng P, Nilsson R, Nishiguchi S, Nishikawa S, Nori F, Ohara O, Okazaki Y, Orlando V, Pang KC, Pavan WJ, Pavesi G, Pesole G, Petrovsky N, Piazza S, Reed J, Reid JF, Ring BZ, Ringwald M, Rost B, Ruan Y, Salzberg SL, Sandelin A, Schneider C, Schönbach C, Sekiguchi K, Semple CA, Seno S, Sessa L, Sheng Y, Shibata Y, Shimada H, Shimada K, Silva D, Sinclair B, Sperling S, Stupka E, Sugiura K, Sultana R, Takenaka Y, Taki K, Tammoja K, Tan SL, Tang S, Taylor MS, Tegner J, Teichmann SA, Ueda HR, van Nimwegen E, Verardo R, Wei CL, Yagi K, Yamanishi H, Zabarovsky E, Zhu S, Zimmer A, Hide W, Bult C, Grimmond SM, Teasdale RD, Liu ET, Brusic V, Quackenbush J, Wahlestedt C, Mattick JS, Hume DA, Kai C, Sasaki D, Tomaru Y, Fukuda S, Kanamori-Katayama M, Suzuki M, Aoki J, Arakawa T, Iida J, Imamura K, Itoh M, Kato T, Kawaji H, Kawagashira N, Kawashima T, Kojima M, Kondo S, Konno H, Nakano K, Ninomiya N, Nishio T, Okada M, Plessy C, Shibata K, Shiraki T, Suzuki S, Tagami M, Waki K, Watahiki A, Okamura-Oho Y, Suzuki H, Kawai J, Hayashizaki Y; FANTOM Consortium; RIKEN Genome Exploration Research Group and Genome Science Group (Genome Network Project Core Group) 2005 The transcriptional landscape of the mammalian genome. Science 309:1559-1563.
25. Ai M, Holmen SL, Van Hul W, Williams BO, Warman ML 2005 Reduced affinity to and inhibition by DKK1 form a common mechanism by which high bone mass-associated missense mutations in LRP5 affect canonical Wnt signaling. Mol Cell Biol 25:4946-4955.
26. Horwood NJ, Elliott J, Martin TJ, Gillespie MT 1998 Osteotropic agents regulate the expression of osteoclast differentiation factor and osteoprotegerin in osteoblastic stromal cells. Endocrinology 139:4743-4746.
27. Glass DA II, Bialek P, Ahn JD, Starbuck M, Patel MS, Clevers H, Taketo MM, Long F, McMahon AP, Lang RA, Karsenty G 2005 Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation. Dev Cell 8:751-764.
28. Holmen SL, Zylstra CR, Mukherjee A, Sigler RE, Faugere M-C, Bouxsein ML, Deng L, Clemens TL, Williams BO 2005 Essential Role of β-catenin in postnatal bone acquisition. J Biol Chem 280:21162-21168.
29. Li X, Liu P, Liu W, Maye P, Zhang J, Zhang Y, Hurley M, Guo C, Boskey A, Sun L, Harris SE, Rowe DW, Ke HZ, Wu D 2005 Dkk2 has a role in terminal osteoblast differentiation and mineralized matrix formation. Nat Genet 37:945-952.
30. Spencer GJ, Utting JC, Etheridge SL, Arnett TR, Genever PG 2006 Wnt signaling in osteoblasts regulates expression the receptor activator of NFκB ligand and inhibits osteoclastogenesis in vitro. J Cell Sci 119:1283-1296.
31. Shin CS, Her SL, Kim JA, Kim DH, Kim SW, Kim SY, Kim HS, Park KH, Kim JG, Kitazawa R, Cheng SL, Civitelli R 2005 Dominant negative N-cadherin inhibits osteoclast differentiation by interfering with β-catenin regulation of RANKL, independent of cell-cell adhesion. J Bone Miner Res 20:2200-2212.
32. Kim S, Yamazaki M, Zella LA, Shevde NK, Pike JW 2006 Activation of receptor activator of NF-kappaB ligand gene expression by 1,25-dihydroxyvitamin D3 is mediated through multiple long-range enhancers. Mol Cell Biol 26:6469-6486.
33. Wang FS, Ko JY, Lin CL, Wu HL, Ke HJ, Tai PJ 2007 Knocking down dickkopf-1 alleviates estrogen deficiency induction of bone loss. A histomorphological study in ovariectomized rats. Bone 40:485-492.
34. Zhang Y, Wang Y, Li X, Zhang J, Mao J, Li Z, Zheng J, Li L, Harris S, Wu D 2004 The LRP5 high-bone-mass G171V mutation disrupts LRP5 interaction with Mesd. Mol Cell Biol 24:4677-4684.
35. Semenov MV, He X 2006 LRP5 mutations linked to high bone mass diseases cause reduced LRP5 binding and inhibition by SOST. J Biol Chem 281:38276-38284.
36. Balemans W, Van Hul W 2007 The genetics of low-density lipoprotein receptor-related protein 5 in bone: A story of extremes. Endocrinology 148:2622-2629.
37. Li Y, Chen J, Lu W, McCormick LM, Wang J, Bu G 2005 Mesd binds to mature LDL-receptor-related protein 6 and antagonizes ligand binding. J Cell Sci 118:5305-5314.